A novel peroxisome proliferator-activated receptor (PPAR)α agonist and PPARy antagonist, Z-551, ameliorates high-fat diet-induced obesity and metabolic disorders in mice

Journal of Biological Chemistry

Volumn 290, Issue 23, 2015, Pages 14567-14581

  Shiomi, Yoshihiro ^a,c   Yamauchi, Toshimasa ^a,b   Iwabu, Masato ^a   Okada Iwabu, Miki ^a   Nakayama, Ryo ^a   Orikawa, Yuki ^c   Yoshioka, Yoshichika ^d   Tanaka, Koichiro ^c,e   Ueki, Kohjiro ^a   Kadowaki, Takashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c ZERIA PHARMACEUTICAL CO LTD   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e AINO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHROPOMETRY; CYTOLOGY; GLUCOSE; INSULIN; MAMMALS; METABOLISM; MOLECULES; NUTRITION; PATHOLOGY; SYNTHESIS (CHEMICAL); TISSUE;

ADIPOCYTE HYPERTROPHY; ANTAGONISTIC ACTIVITY; INSULIN RESISTANCE; LIPID METABOLISMS; MACROPHAGE INFILTRATIONS; METABOLIC DISORDERS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PLASMA TRIGLYCERIDES;

FATTY ACIDS;

FATTY ACID; GLUCOSE; INSULIN; LEPTIN; MONOSODIUM 2 [9 [[3 METHOXY 4 [[5 METHYL 2 PHENYL(1,3 OXAZOL 4 YL)]METHOXY]PHENYL]METHYL]CARBAZOL 4 YLOXY] 2 METHYLPROPANOATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIRINIXIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHESIS; FATTY ACID TRANSPORT; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HORMONE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID DIET; LIPID METABOLISM; MALE; METABOLIC DISORDER; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ADVERSE EFFECTS; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; DRUG EFFECTS; METABOLISM; PATHOLOGY;

MUS;

ANIMALS; CELL LINE; DIET, HIGH-FAT; GLUCOSE; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; OBESITY; PPAR ALPHA; PPAR GAMMA;

EID: 84930618748     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.622191     Document Type: Article

References (55)

1. Flegal, K. M., and Carroll., M. D., Ogden, C. L., and Curtin, L. R. (2010) Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303, 235-241
2. Kopelman, P. G. (2000) Obesity as a medical problem. Nature 404, 635-643
3. Ahima, R. S. (2006) Adipose tissue as an endocrine organ. Obesity 14, 242S-249S
4. Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L., and Spiegelman, B. M. (1995) Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95, 2409-2415
5. Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., and Leibel., R. L., and Ferrante, A. W. Jr. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796-1808
6. Xu, H., and Barnes., G. T., Yang, Q., Tan, G., Yang, D., and Chou., C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., and Chen, H. (2003) Chronic inflammation in fat plays a crucial role in the development of obesityrelated insulin resistance. J. Clin. Invest. 112, 1821-1830
7. Desvergne, B., and Wahli, W. (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649-688
8. Evans, R. M., Barish, G.D., and Wang, Y.X. (2004) PPARs and the complex journey to obesity. Nat. Med. 10, 355-361
9. Lefebvre, P., Chinetti, G., Fruchart, J. C, and Staels, B. (2006) Sorting out the roles of PPARa in energy metabolism and vascular homeostasis. J. Clin. Invest. 116, 571-580
10. Aoyama, T., and Peters., J. M., Iritani, N, Nakajima, T., Furihata, K., Hashimoto, T., and Gonzalez, F. J. (1998) Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARa). J. Biol. Chem. 273, 5678-5684
11. Tsuchida, A., Yamauchi, T., Takekawa, S., Hada, Y., Ito, Y., Maki, T., and Kadowaki, T. (2005) Peroxisome proliferator-activated receptor (PPAR)a activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARa, PPAR7 and their combination. Diabetes 54, 3358-3370
12. Guerre-Millo, M., Gervois, P., Raspé, E., Madsen, L., Poulain, P., Derudas, B., Herbert, J. M., Winegar, D. A., Willson, T. M., Fruchart, J. C, Berge, R. K., and Staels, B. (2000) Peroxisome proliferator-activated receptor a activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275, 16638-16642
13. Minnich, A., Tian, N., Byan, L., and Bilder, G. (2001) A potent PPARa agonist stimulates mitochondrial fatty acid β-oxidation in liver and skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 280, E270-E279
14. Haluzík, M. M., and Haluzík, M. (2006) PPAR-α and insulin sensitivity. Physiol. Res. 55, 115-122
15. Jeong, S., and Yoon, M. (2009) Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARa in high fat diet-induced obese mice. Exp. Mol. Med. 41, 397-405
16. Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., and Spiegelman, B. M. (1994) mPPAR γ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8, 1224-1234
17. Okuno, A., Tamemoto, H., Tobe, K., Ueki, K., Mori, Y., Iwamoto, K., Umesono, K., Akanuma, Y., Fujiwara, T., Horikoshi, H., Yazaki, Y., and Kadowaki, T. (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101, 1354-1361
18. Yamauchi, T., Kamon, J., Waki, H., Murakami, K., Motojima, K., Komeda, K., Ide, T., Kubota, N., Terauchi, Y., Tobe, K., Miki, H., Tsuchida, A., Akanuma, Y., Nagai, R., Kimura, S., and Kadowaki, T. (2001) The mechanisms by which both heterozygous peroxisome proliferator-activated receptor 7 (PPAR7) deficiency and PPAR7 agonist improve insulin resistance. J. Biol. Chem. 276, 41245-41254
19. Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C, Sugiyama, T., Eto, K., Tsubamoto, Y., Okuno, A., Murakami, K., Sekihara, H., Hasegawa, G., Naito, M., Toyoshima, Y., Tanaka, S., Shiota, K., Kitamura, T., Fujita, T., Ezaki, O., Aizawa, S., Nagai, R., Tobe, K., Kimura, S., and Kadowaki, T. (1999) PPAR7 mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4, 597-609
20. Kadowaki, T. (2000) Insights into insulin resistance and type 2 diabetes from knockout mouse models. J. Clin. Invest. 106, 459-465
21. Deeb, S. S., Fajas, L., Nemoto, M., Pihlajamäki, J., Mykkänen, L., Kuusisto, J., Laakso, M., Fujimoto, W., and Auwerx, J. (1998) A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 20, 284-287
22. Hara, K., Okada, T., Tobe, K., Yasuda, K., Mori, Y., Kadowaki, H., Hagura, R., Akanuma, Y., Kimura, S., Ito, C, and Kadowaki, T. (2000) The Pro12Ala polymorphism in PPAR γ2 may confer resistance to type 2 diabetes. Biochem. Biophys. Res. Commun. 271, 212-216
23. Yamauchi, T., Waki, H., Kamon, J., Murakami, K., Motojima, K., Komeda, K., Miki, H., Kubota, N, Terauchi, Y., Tsuchida, A., Tsuboyama-Kasaoka, N., Yamauchi, N., Ide, T., Hori, W., Kato, S., Fukayama, M., Akanuma, Y., Ezaki, O., Itai, A., Nagai, R., Kimura, S., Tobe, K., Kagechika, H., Shudo, K., and Kadowaki, T. (2001) Inhibition of RXR and PPAR7 ameliorates dietinduced obesity and type 2 diabetes. J. Clin. Invest. 108, 1001-1013
24. Rieusset, J., Touri, F., Michalik, L., Escher, P., Desvergne, B., Niesor, E., and Wahli, W. (2002) A new selective peroxisome proliferator-activated receptor 7 antagonist with antiobesity and antidiabetic activity. Mol. Endocrinol. 16, 2628-2644
25. Nakano, R., Kurosaki, E., Yoshida, S., Yokono, M., Shimaya, A., Maruyama, T., and Shibasaki, M. (2006) Antagonism of peroxisome proliferator-activated receptor 7 prevents high-fat diet-induced obesity in vivo. Biochem. Pharmacol. 72, 42-52
26. Cock, T. A., and Houten., S. M., and Auwerx, J. (2004) Peroxisome proliferator-activated receptor-7: too much of a good thing causes harm. EMBO Rep. 5, 142-147
27. Ikemoto, S., and Thompson., K. S., Takahashi, M., Itakura, H., Lane, M. D., and Ezaki, O. (1995) High fat diet-induced hyperglycemia: prevention by low level expression of a glucose transporter (GLUT4) minigene in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 92, 3096-3099
28. Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., Ezaki, O., Akanuma, Y., Gavrilova, O., Vinson, C, Reitman, M.L., Kagechika, H., Shudo, K., Yoda, M., Nakano, Y., Tobe, K., Nagai, R., Kimura, S., Tomita, M., Froguel, P., and Kadowaki, T. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 7, 941-946
29. Miyake, K., Ogawa, W., Matsumoto, M., Nakamura, T., Sakaue, H., and Kasuga, M. (2002) Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver. J. Clin. Invest. 110, 1483-1491
30. Iwabu, M., Yamauchi, T., Okada-Iwabu, M., Sato, K., Nakagawa, T., Funata, M., Yamaguchi, M., Namiki, S., Nakayama, R., Tabata, M., Ogata, H., Kubota, N., Takamoto, I., and Hayashi., Y. K., Yamauchi, N., Waki, H., Fukayama, M., Nishino, I., Tokuyama, K., Ueki, K., Oike, Y., Ishii, S., Hirose, K., Shimizu, T., Touhara, K., and Kadowaki, T. (2010) Adiponectin and AdipoR1 regulate PGC-1α and mitochondria by Ca2+ and AMPK/SIRT1. Nature 464, 1313-1319
31. Nio, Y., Yamauchi, T., Iwabu, M., Okada-Iwabu, M., Funata, M., Yamaguchi, M., Ueki, K., and Kadowaki, T. (2012) Monocyte chemoattractant protein-1 (MCP-1) deficiency enhances alternatively activated M2 macrophages and ameliorates insulin resistance and fatty liver in lipoatrophic diabetic A-ZIP transgenic mice. Diabetologia 55, 3350-3358
32. Watanabe, T., Kubota, N., Ohsugi, M., Kubota, T., Takamoto, I., Iwabu, M., Awazawa, M., Katsuyama, H., Hasegawa, C, Tokuyama, K., Moroi, M., Sugi, K., Yamauchi, T., Noda, T., Nagai, R., Terauchi, Y., Tobe, K., Ueki, K., and Kadowaki, T. (2009) Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J. Biol. Chem. 284, 1803-1812
33. Nonaka, K., and Uchiyama, S. (2011) Assessment of volumetric bone mineral density and geometry for hip with clinical CT device. Clin. Calcium 21, 1003-1009
34. Mori, Y., Murakami, M., Arima, Y., Zhu, D., Terayama, Y., Komai, Y., Nakatsuji, Y., Kamimura, D., and Yoshioka, Y. (2014) Early pathological alterations of lower lumber cords detected by ultra-high field MRI in a mouse multiple sclerosis model. Int. Immunol. 26, 93-101
35. Ali, A. A., and Weinstein., R. S., Stewart, S. A., Parfitt, A. M., Manolagas, S. C, and Jilka, R. L. (2005) Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146, 1226-1235
36. Friedman, J. M., and Halaas, J. L. (1998) Leptin and the regulation of body weight in mammals. Nature 395, 763-770
37. Auwerx, J., and Staels, B. (1998) Leptin. Lancet 351, 737-742
38. Spiegelman, B. M., and Flier, J. S. (2001) Obesity and the regulation of energy balance. Cell 104, 531-543
39. Uysal, K. T., and Wiesbrock., S. M., Marino, M. W., and Hotamisligil, G. S. (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389, 610-614
40. Kamei, N., Tobe, K., Suzuki, R., Ohsugi, M., Watanabe, T., Kubota, N, Ohtsuka-Kowatari, N, Kumagai, K., Sakamoto, K., Kobayashi, M., Yamauchi, T., Ueki, K., Oishi, Y., Nishimura, S., Manabe, I., Hashimoto, H., Ohnishi, Y., Ogata, H., Tokuyama, K., Tsunoda, M., Ide, T., Murakami, K., Nagai, R., and Kadowaki, T. (2006) Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J. Biol. Chem. 281, 26602-26614
41. Toyoda, T., Kamei, Y., Kato, H., Sugita, S., Takeya, M., Suganami, T., and Ogawa, Y. (2008) Effect of peroxisome proliferator-activated receptor-α ligands in the interaction between adipocytes and macrophages in obese adipose tissue. Obesity 16, 1199-1207
42. Bouhlel, M. A., Derudas, B., Rigamonti, E., Dièvart, R., Brozek, J., Haulon, S., Zawadzki, C, Jude, B., Torpier, G., Marx, N, Staels, B., and Chinetti-Gbaguidi, G. (2007) PPAR7 activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6, 137-143
43. Lumeng, C. N, Bodzin, J. L., and Saltiel, A. R. (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175-184
44. Fujisaka, S., Usui, I., Bukhari, A., Ikutani, M., Oya, T., Kanatani, Y., Tsuneyama, K., Nagai, Y., Takatsu, K., Urakaze, M., Kobayashi, M., and Tobe, K. (2009) Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 58, 2574-2582
45. Suganami, T., and Ogawa, Y. (2010) Adipose tissue macrophages: their role in adipose tissue remodeling. J. Leukoc. Biol. 88, 33-39
46. Murakami, K., Bujo, H., Unoki, H., and Saito, Y. (2007) Effect of PPARa activation of macrophages on the secretion of inflammatory cytokines in cultured adipocytes. Eur. J. Pharmacol. 561, 206-213
47. Suganami, T., Nishida, J., and Ogawa, Y. (2005) A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor α. Arterioscler. Thromb. Vasc. Biol. 25, 2062-2068
48. Inoue, I., Noji, S., Shen, M. Z., Takahashi, K., and Katayama, S. (1997) The peroxisome proliferator-activated receptor α (PPARa) regulates the plasma thiobarbituric acid-reactive substance (TBARS) level. Biochem. Biophys. Res. Commun. 237, 606-610
49. Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., and Shimomura, I. (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114, 1752-1761
50. Lehrke, M., and Lazar, M. A. (2005) The many faces of PPARγ. Cell 123, 993-999
51. Nissen, S. E., and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471
52. Cariou, B., Charbonnel, B., and Staels, B. (2012) Thiazolidinediones and PPAR7 agonists: time for a reassessment. Trends Endocrinol. Metab. 23, 205-215
53. Ahmadian, M., and Suh., J. M., Hah, N, Liddle, C., and Atkins., A. R., Downes, M., and Evans, R. M. (2013) PPAR7 signaling and metabolism: the good, the bad and future. Nat. Med. 19, 557-566
54. Morimura, K., Cheung, C., Ward, J. M., Reddy, J. K., and Gonzalez, F. J. (2006) Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor a to Wy-14, 643-induced liver tumorigenesis. Carcinogenesis 27, 1074-1080
55. Gonzalez, F. J., and Shah, Y. M. (2008) PPARa: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246, 2-8